CoapTech

CoapTech is a private medical device company pioneering point-of-care access procedures with its proprietary PUMA Platform. Its flagship product, the PUMA-G System, enables Percutaneous Ultrasound Gastrostomy (PUG), a bedside procedure that clinical studies associate with significantly reduced ICU length of stay, hospital costs, and procedural risks compared to traditional methods. The company is positioned to disrupt the $2B+ global gastrostomy market by shifting procedures from specialized suites to the bedside, improving hospital efficiency and patient access.

The PUMA System™ platform uses magnetic coaptation and point-of-care ultrasound guidance to enable safe, percutaneous access to hollow organs at the bedside, eliminating the need for endoscopy, fluoroscopy, or an operating room.

CoapTech competes with established gastrostomy methods: Percutaneous Endoscopic Gastrostomy (PEG) supported by endoscopy companies (e.g., Olympus, Boston Scientific) and Percutaneous Radiologic Gastrostomy (PRG) supported by interventional radiology. Its unique value proposition is being the only FDA-cleared, purely ultrasound-based bedside solution, positioning it as a disruptor to these resource-intensive, suite-dependent standards of care.